Locust Walk Sponsor, LLC - 25 Aug 2021 Form 4 Insider Report for eFFECTOR Therapeutics, Inc.

Role: 10%+ Owner
Signature: /s/ Chris Ehrlich, Chief Executive Officer
Issuer symbol: EFTR on OTC
Transactions as of: 25 Aug 2021
Net transactions value: $0
Form type: 4
Filing time: 27 Aug 2021, 18:31:16 UTC
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EFTR	Common Stock	Conversion of derivative security	$0	+3,511,250	+644%	$0.000000	4,056,250	25 Aug 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EFTR	Class B Common Stock	Disposed to Issuer	$0	-1,000,000	-22%	$0.000000	3,511,250	25 Aug 2021	Common Stock	1,000,000		Direct	F1, F2
transaction	EFTR	Class B Common Stock	Conversion of derivative security		-3,511,250	-100%		0	25 Aug 2021	Common Stock	3,511,250		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On August 25, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of May 26, 2021 (the "Merger Agreement"), by and among the Issuer (f/k/a Locust Walk Acquisition Corp.), Locust Walk Merger Sub, Inc. ("Merger Sub"), and eFFECTOR Therapeutics, Inc. ("Old eFFECTOR"), Merger Sub merged with and into Old eFFECTOR with Old eFFECTOR surviving as a wholly owned subsidiary of the Issuer (the "Merger"). In connection with and upon consummation of the Merger, each of the Issuer's outstanding shares of Class B Common Stock automatically converted into one share of Class A Common Stock and such shares of Class A Common Stock were automatically reclassified in shares of common stock.
F2	Pursuant to an agreement by and between the Issuer and the reporting person, concurrent with the consummation of the Merger, these shares of Class B Common Stock were forfeited to the Issuer immediately prior to the Merger.

Content

On August 25, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of May 26, 2021 (the "Merger Agreement"), by and among the Issuer (f/k/a Locust Walk Acquisition Corp.), Locust Walk Merger Sub, Inc. ("Merger Sub"), and eFFECTOR Therapeutics, Inc. ("Old eFFECTOR"), Merger Sub merged with and into Old eFFECTOR with Old eFFECTOR surviving as a wholly owned subsidiary of the Issuer (the "Merger"). In connection with and upon consummation of the Merger, each of the Issuer's outstanding shares of Class B Common Stock automatically converted into one share of Class A Common Stock and such shares of Class A Common Stock were automatically reclassified in shares of common stock.

Pursuant to an agreement by and between the Issuer and the reporting person, concurrent with the consummation of the Merger, these shares of Class B Common Stock were forfeited to the Issuer immediately prior to the Merger.